SMS Lifesciences India Ltd
Incorporated in 2006, SMS Lifesciences Ltd is in the business of manufacturing of Active Pharma Ingredients and their intermediates[1]
- Market Cap ₹ 208 Cr.
- Current Price ₹ 688
- High / Low ₹ 790 / 464
- Stock P/E 23.9
- Book Value ₹ 554
- Dividend Yield 0.21 %
- ROCE 9.13 %
- ROE 7.34 %
- Face Value ₹ 10.0
Pros
Cons
- The company has delivered a poor sales growth of 8.11% over past five years.
- Company has a low return on equity of 9.77% over last 3 years.
- Dividend payout has been low at 2.88% of profits over last 3 years
- Debtor days have increased from 43.5 to 52.7 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
0 | 0 | 0 | 0 | 0 | 218 | 213 | 344 | 257 | 260 | 346 | 315 | 279 | |
0 | 0 | 0 | 0 | 0 | 189 | 200 | 312 | 233 | 230 | 314 | 289 | 253 | |
Operating Profit | 0 | 0 | 0 | 0 | 0 | 28 | 13 | 33 | 24 | 30 | 31 | 26 | 26 |
OPM % | 13% | 6% | 9% | 9% | 11% | 9% | 8% | 9% | |||||
0 | 0 | 0 | 0 | 0 | 2 | 3 | 2 | 2 | 1 | 14 | 5 | 6 | |
Interest | 0 | 0 | 0 | 0 | 0 | 6 | 4 | 5 | 5 | 5 | 5 | 5 | 8 |
Depreciation | 0 | 0 | 0 | 0 | 0 | 6 | 6 | 6 | 7 | 7 | 8 | 8 | 10 |
Profit before tax | 0 | 0 | 0 | 0 | 0 | 18 | 6 | 24 | 13 | 19 | 33 | 18 | 15 |
Tax % | 30% | -2% | 30% | 31% | 32% | 23% | 28% | ||||||
0 | 0 | 0 | 0 | 0 | 13 | 6 | 17 | 9 | 13 | 25 | 13 | 10 | |
EPS in Rs | 21.50 | 55.01 | 30.26 | 43.56 | 83.95 | 43.73 | 31.76 | ||||||
Dividend Payout % | 0% | 0% | 3% | 0% | 3% | 2% | 3% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | 8% |
3 Years: | 7% |
TTM: | -19% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | 12% |
3 Years: | 8% |
TTM: | -42% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | 4% |
3 Years: | 4% |
1 Year: | 24% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | 11% |
3 Years: | 10% |
Last Year: | 7% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Sep 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
Reserves | 0 | 0 | 0 | -0 | -0 | 82 | 85 | 102 | 110 | 123 | 148 | 161 | 164 |
0 | 0 | 0 | 0 | 0 | 26 | 27 | 47 | 50 | 45 | 62 | 87 | 95 | |
0 | 0 | 0 | 0 | 0 | 67 | 61 | 98 | 66 | 101 | 99 | 86 | 71 | |
Total Liabilities | 0 | 0 | 0 | 0 | 0 | 175 | 177 | 251 | 229 | 272 | 312 | 337 | 334 |
0 | 0 | 0 | 0 | 0 | 73 | 69 | 88 | 94 | 101 | 99 | 140 | 135 | |
CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 7 | 1 | 2 | 3 | 21 | 1 | 8 |
Investments | 0 | 0 | 0 | 0 | 0 | 0 | 5 | 26 | 26 | 26 | 23 | 23 | 23 |
0 | 0 | 0 | 0 | 0 | 102 | 95 | 135 | 106 | 142 | 169 | 174 | 168 | |
Total Assets | 0 | 0 | 0 | 0 | 0 | 175 | 177 | 251 | 229 | 272 | 312 | 337 | 334 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
0 | 0 | 0 | 0 | 0 | 20 | 8 | 27 | 14 | 22 | -15 | 5 | |
0 | 0 | 0 | 0 | 0 | -8 | -7 | -43 | -13 | -6 | -7 | -28 | |
0 | 0 | 0 | 0 | 0 | -12 | -1 | 18 | -2 | -8 | 15 | 23 | |
Net Cash Flow | 0 | 0 | 0 | 0 | 0 | -0 | 0 | 2 | -1 | 8 | -8 | -1 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 65 | 46 | 39 | 31 | 42 | 36 | 53 | |||||
Inventory Days | 133 | 135 | 117 | 138 | 154 | 143 | 154 | |||||
Days Payable | 168 | 122 | 133 | 102 | 147 | 124 | 105 | |||||
Cash Conversion Cycle | 30 | 60 | 23 | 67 | 48 | 54 | 102 | |||||
Working Capital Days | 50 | 51 | 34 | 57 | 63 | 79 | 111 | |||||
ROCE % | 0% | 0% | 0% | 0% | 46% | 9% | 22% | 12% | 14% | 13% | 9% |
Documents
Announcements
- Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 16h
-
Compliance Certificate (PCS)
22 Apr - Disclosure pursuant to Regulation 40 of SEBI (Listing Obligations & Disclosure Requirments) Regulations, 2015.
- Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 11 Apr
-
Compliance Certificate (RTA)
11 Apr - Disclosure pursuant to Reg. 7(3) of SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015.
- Large Corporate (Not Applicable) 5 Apr
Business Overview:[1][2][3]
Company is the demerged entity of SMS Pharmaceuticals Ltd, catering to semi-regulated markets across India, Europe, and Asia with a portfolio of 12 APIs in the GAS and Anti-erectile dysfunction (EDF) therapeutic segment. It does manufacturing of Antiulcerative products, for Indian and global markets and supplies KSMs and Intermediates